Theravance Biopharma, Inc. (TBPH)
17.03
0.00 (0.00%)
USD |
NASDAQ |
Oct 02, 16:00
Theravance Biopharma Enterprise Value : 567.41M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 567.41M |
| October 01, 2026 | 567.41M |
| September 30, 2026 | 567.41M |
| September 29, 2026 | 567.41M |
| September 28, 2026 | 567.41M |
| September 25, 2026 | 567.41M |
| September 24, 2026 | 567.41M |
| September 23, 2026 | 567.41M |
| September 22, 2026 | 567.41M |
| September 21, 2026 | 568.45M |
| September 18, 2026 | 566.89M |
| September 17, 2026 | 567.93M |
| September 16, 2026 | 567.41M |
| September 15, 2026 | 567.93M |
| September 14, 2026 | 567.41M |
| September 11, 2026 | 566.37M |
| September 10, 2026 | 566.89M |
| September 09, 2026 | 568.97M |
| September 08, 2026 | 568.97M |
| September 04, 2026 | 570.01M |
| September 03, 2026 | 570.01M |
| September 02, 2026 | 569.49M |
| September 01, 2026 | 567.41M |
| August 31, 2026 | 567.93M |
| August 28, 2026 | 568.45M |
| Date | Value |
|---|---|
| August 27, 2026 | 567.93M |
| August 26, 2026 | 567.41M |
| August 25, 2026 | 567.41M |
| August 24, 2026 | 566.37M |
| August 21, 2026 | 566.37M |
| August 20, 2026 | 563.26M |
| August 19, 2026 | 565.34M |
| August 18, 2026 | 563.26M |
| August 17, 2026 | 561.70M |
| August 14, 2026 | 564.30M |
| August 13, 2026 | 561.70M |
| August 12, 2026 | 561.70M |
| August 11, 2026 | 561.70M |
| August 10, 2026 | 561.18M |
| August 07, 2026 | 562.22M |
| August 06, 2026 | 561.70M |
| August 05, 2026 | 560.66M |
| August 04, 2026 | 559.63M |
| August 03, 2026 | 559.11M |
| July 31, 2026 | 558.59M |
| July 30, 2026 | 558.07M |
| July 29, 2026 | 558.07M |
| July 28, 2026 | 560.15M |
| July 27, 2026 | 558.59M |
| July 24, 2026 | 558.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Viatris, Inc. | 32.55B |
| Ocular Therapeutix, Inc. | 1.009B |
| ANI Pharmaceuticals, Inc. | 1.893B |
| Corcept Therapeutics, Inc. | 12.24B |
| Veru, Inc. | 19.69M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.898M |
| Revenue (Quarterly) | 20.73M |
| Total Expenses (Quarterly) | 26.63M |
| EPS Diluted (Quarterly) | -0.1142 |
| Gross Profit Margin (Quarterly) | 93.04% |
| Profit Margin (Quarterly) | -28.45% |
| Earnings Yield | 5.93% |
| Operating Earnings Yield | 0.25% |
| Normalized Earnings Yield | 7.024 |